ENETS Abstract Search

Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Functional and Metastatic Phaeochromocytoma (PCC) and Paraganglioma (PGL)

#1784

Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.

Aim(s): We assessed PRRT outcomes in patients (pts) with high somatostatin receptor (SSTR) expression from 2 referral centres.

Materials and methods: 16 pts (M:F=11:5; 21-77y.o) treated with 177Lu-DOTA-octreotate were retrospectively reviewed. Median cumulative activity 21.5 GBq, most had 4 cycles, 7 had radiosensitising chemotherapy. 4 pts had SDHB mutation, 1 SDHD, 2 negative and 9 unknown. 12 pts were treated for secondary HTN and 4 pts for non-functional metastatic disease/recurrence.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: kong G

Authors: Kong G, Grozinsky-Glasberg S, Callahan J, Hofman M, Meirovitz A,

Keywords: PRRT,

To read the full abstract, please log into your ENETS Member account.